JOP20170136B1 - ستخدام مركبات إندازول مستبدل في الموقع 2 للمعالجة والوقاية من اضطرابات المناعة الذاتية - Google Patents

ستخدام مركبات إندازول مستبدل في الموقع 2 للمعالجة والوقاية من اضطرابات المناعة الذاتية

Info

Publication number
JOP20170136B1
JOP20170136B1 JOP/2017/0136A JOP20170136A JOP20170136B1 JO P20170136 B1 JOP20170136 B1 JO P20170136B1 JO P20170136 A JOP20170136 A JO P20170136A JO P20170136 B1 JOP20170136 B1 JO P20170136B1
Authority
JO
Jordan
Prior art keywords
prophylaxis
treatment
autoimmune disorders
arthritis
substituted indazoles
Prior art date
Application number
JOP/2017/0136A
Other languages
English (en)
Inventor
Rausch Alexandra
Joachim JODL Stefan
Kratzschmar Jorn
Bothe Ulrich
Schmidt Nicole
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JOP20170136B1 publication Critical patent/JOP20170136B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات indazoles مستبدلة، لاستخدامها لوحدها أو في توليفات للمعالجة و/أو الوقاية من اضطرابات المناعة الذاتية، ولاستخدامها لإنتاج دواء للمعالجة و/أو الوقاية من اضطرابات المناعة الذاتية، وعلى نحو خاص للمعالجة و/أو الوقاية من التهاب المفاصل (خصوصا الْتِهاب المَفْصِلِ في الصَّدَفِيَّة، التهاب المفاصل الروماتيدي، داء بِختِيرِيف، التهاب المفاصل الارتكاسي، التهاب المفاصل مجهول السبب اليفعي الجهازي)، الذئبة الحمامية المجموعية، التصلب المتعدد، الصدفية، التهاب الجلد التأتبي، إِكْزيمَة أَرَجِيَّة، واضطرابات الأمعاء الالتهابية- المزمنة (خصوصا مرض كرون والتهاب القولون التقرحي).
JOP/2017/0136A 2016-06-01 2017-05-31 ستخدام مركبات إندازول مستبدل في الموقع 2 للمعالجة والوقاية من اضطرابات المناعة الذاتية JOP20170136B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172507 2016-06-01

Publications (1)

Publication Number Publication Date
JOP20170136B1 true JOP20170136B1 (ar) 2023-09-17

Family

ID=56097014

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0136A JOP20170136B1 (ar) 2016-06-01 2017-05-31 ستخدام مركبات إندازول مستبدل في الموقع 2 للمعالجة والوقاية من اضطرابات المناعة الذاتية

Country Status (20)

Country Link
US (3) US20190125736A1 (ar)
EP (1) EP3463354A1 (ar)
JP (1) JP7099966B2 (ar)
KR (1) KR102460362B1 (ar)
CN (1) CN109152771B (ar)
AU (1) AU2017273771B2 (ar)
CA (1) CA3025826A1 (ar)
CL (1) CL2018003409A1 (ar)
EA (1) EA201892790A1 (ar)
IL (1) IL263230B (ar)
JO (1) JOP20170136B1 (ar)
MA (1) MA45089A (ar)
MX (1) MX2018014897A (ar)
NZ (1) NZ748907A (ar)
PH (1) PH12018502531A1 (ar)
SG (2) SG10202011653WA (ar)
TN (1) TN2018000409A1 (ar)
TW (1) TWI784954B (ar)
UA (1) UA123916C2 (ar)
WO (1) WO2017207386A1 (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017186689A1 (en) 2016-04-29 2017-11-02 Bayer Pharma Aktiengesellschaft Synthesis of indazoles
EP3448849B1 (en) 2016-04-29 2020-05-13 Bayer Pharma Aktiengesellschaft Synthesis of indazoles
MX394560B (es) 2016-06-01 2025-03-24 Bayer Pharma AG Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales.
WO2020036830A1 (en) * 2018-08-13 2020-02-20 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
WO2021011727A1 (en) * 2019-07-18 2021-01-21 Bristol-Myers Squibb Company PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
JP7555519B2 (ja) 2022-02-14 2024-09-24 アストラゼネカ・アクチエボラーグ Ｉｒａｋ４阻害剤
US20250326757A1 (en) 2022-05-26 2025-10-23 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors
WO2024108010A1 (en) * 2022-11-17 2024-05-23 Bayer Animal Health Gmbh Methods and compositions for control of pain and inflammation
CN121773099A (zh) 2023-08-11 2026-03-31 阿斯利康(瑞典)有限公司 结晶irak4抑制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (es) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos.
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
US20080161365A1 (en) 2004-12-08 2008-07-03 Pfizer Inc. Methylene Derivatives
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
JP5258563B2 (ja) 2006-06-29 2013-08-07 日産化学工業株式会社 αアミノ酸誘導体及びそれを有効成分として含む医薬
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2012061926A1 (en) 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
WO2012107475A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
HK1206723A1 (en) 2012-05-21 2016-01-15 Bayer Pharma Aktiengesellschaft Thienopyrimidines
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EP3092226B1 (en) * 2014-01-10 2019-03-13 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
AU2015275730A1 (en) * 2014-06-20 2016-12-15 Aurigene Discovery Technologies Limited Substituted indazole compounds as IRAK4 inhibitors
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
JP2018524372A (ja) 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
EP3448849B1 (en) * 2016-04-29 2020-05-13 Bayer Pharma Aktiengesellschaft Synthesis of indazoles
WO2017186689A1 (en) 2016-04-29 2017-11-02 Bayer Pharma Aktiengesellschaft Synthesis of indazoles
MX394560B (es) 2016-06-01 2025-03-24 Bayer Pharma AG Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales.

Also Published As

Publication number Publication date
US11992481B2 (en) 2024-05-28
NZ748907A (en) 2023-04-28
MX2018014897A (es) 2019-04-24
US20210085664A1 (en) 2021-03-25
TW201742862A (zh) 2017-12-16
CA3025826A1 (en) 2017-12-07
AU2017273771A1 (en) 2018-12-20
BR112018074919A2 (pt) 2020-11-03
TN2018000409A1 (en) 2020-06-15
WO2017207386A1 (de) 2017-12-07
MA45089A (fr) 2019-04-10
KR20190015251A (ko) 2019-02-13
TWI784954B (zh) 2022-12-01
JP2019517495A (ja) 2019-06-24
SG10202011653WA (en) 2020-12-30
UA123916C2 (uk) 2021-06-23
JP7099966B2 (ja) 2022-07-12
IL263230B (en) 2021-09-30
SG11201810769QA (en) 2018-12-28
CL2018003409A1 (es) 2019-03-22
EP3463354A1 (de) 2019-04-10
HK1258914A1 (zh) 2019-11-22
IL263230A (en) 2019-01-31
CN109152771B (zh) 2022-07-19
CN109152771A (zh) 2019-01-04
KR102460362B1 (ko) 2022-10-28
EA201892790A1 (ru) 2019-06-28
PH12018502531A1 (en) 2019-10-21
US20220249456A1 (en) 2022-08-11
US20190125736A1 (en) 2019-05-02
AU2017273771B2 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
JOP20170136B1 (ar) ستخدام مركبات إندازول مستبدل في الموقع 2 للمعالجة والوقاية من اضطرابات المناعة الذاتية
CL2024001474A1 (es) Compuestos derivados de heterociclos sustituidos, activadores akt3; composición farmacéutica; y uso
MX2024014319A (es) Anticuerpos anti-bcma unicamente de cadena pesada
TN2017000226A1 (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
NZ790629A (en) Uses of il-13 antagonists for treating atopic dermatitis
MX2018006223A (es) Moduladores de ror-gamma.
TN2015000370A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
MX2016011784A (es) Nuevos heteroarilos y su uso como medicamentos.
TN2015000348A1 (en) Antibodies that bind il-23
MX2011008444A (es) Derivado de heteroanillo.
PH12017500403A1 (en) Anti-il-25 antibodies and uses thereof
MX367335B (es) Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias.
MX2022008800A (es) Sistemas y metodos de control adecuados para el uso con sistemas y metodos de produccion de energia.
Sun Refining Lagrange's four-square theorem
PH12018500533A1 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
PH12018500251A1 (en) Novel compounds as ror gamma modulators
MY193175A (en) Apremilast pharmaceutical compositions
CR20210087A (es) Inhibidores de la interacción proteína-proteína keap1-nrf2
Wu et al. Adaptive anti-synchronization and H∞ anti-synchronization for memristive neural networks with mixed time delays and reaction–diffusion terms
PH12016501105A1 (en) Bicyclic heteroaryl indole analogues useful as ror gamma modulators
JOP20170113B1 (ar) مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
WO2016199170A3 (en) Paliperidone palmitate particles and compositions thereof
EP4537847A3 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
NZ755747A (en) Ampa receptor potentiators
MX371538B (es) Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.